bisoprolol has been researched along with Stroke in 13 studies
Bisoprolol: A cardioselective beta-1 adrenergic blocker. It is effective in the management of HYPERTENSION and ANGINA PECTORIS.
Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)
Excerpt | Relevance | Reference |
---|---|---|
"To examine the effects of combination with levamlodipine and bisoprolol on stroke in rats." | 7.79 | Effects of combination therapy with levamlodipine and bisoprolol on stroke in rats. ( Gui, H; Guo, YF; Huang, GZ; Liu, JG; Liu, X; Yang, YL; Zhang, JM, 2013) |
"The use of metoprolol and atenolol is associated with increased risks of postoperative stroke, compared with bisoprolol." | 7.79 | Selective β1-antagonism with bisoprolol is associated with fewer postoperative strokes than atenolol or metoprolol: a single-center cohort study of 44,092 consecutive patients. ( Ashes, C; Beattie, WS; Hare, GM; Judelman, S; Mazer, CD; Tait, G; Wijeysundera, DN, 2013) |
"The RAte control Therapy Evaluation in permanent Atrial Fibrillation (RATE-AF) trial will enrol 160 participants with a prospective, randomised, open-label, blinded end point design comparing initial rate control with digoxin or bisoprolol." | 5.24 | A review of rate control in atrial fibrillation, and the rationale and protocol for the RATE-AF trial. ( Calvert, M; Deeks, JJ; Griffith, M; Kirchhof, P; Kotecha, D; Lip, GY; Mehta, S; Slinn, G; Stanbury, M; Steeds, RP; Townend, JN, 2017) |
"To examine the effects of combination with levamlodipine and bisoprolol on stroke in rats." | 3.79 | Effects of combination therapy with levamlodipine and bisoprolol on stroke in rats. ( Gui, H; Guo, YF; Huang, GZ; Liu, JG; Liu, X; Yang, YL; Zhang, JM, 2013) |
"The use of metoprolol and atenolol is associated with increased risks of postoperative stroke, compared with bisoprolol." | 3.79 | Selective β1-antagonism with bisoprolol is associated with fewer postoperative strokes than atenolol or metoprolol: a single-center cohort study of 44,092 consecutive patients. ( Ashes, C; Beattie, WS; Hare, GM; Judelman, S; Mazer, CD; Tait, G; Wijeysundera, DN, 2013) |
"Left ventricular hypertrophy was diagnosed using the Sokolow-Lyon indices." | 1.48 | Left ventricular hypertrophy diagnosed after a stroke: a case report. ( Kanyal, R; Umeojiako, WI, 2018) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (7.69) | 29.6817 |
2010's | 11 (84.62) | 24.3611 |
2020's | 1 (7.69) | 2.80 |
Authors | Studies |
---|---|
Iwano, T | 1 |
Toda, H | 1 |
Nakamura, K | 1 |
Shimizu, K | 1 |
Ejiri, K | 1 |
Naito, Y | 1 |
Mori, H | 1 |
Masuda, T | 1 |
Miyoshi, T | 1 |
Yoshida, M | 1 |
Hikasa, Y | 1 |
Morimatsu, H | 1 |
Ito, H | 1 |
Kotecha, D | 1 |
Calvert, M | 1 |
Deeks, JJ | 1 |
Griffith, M | 1 |
Kirchhof, P | 1 |
Lip, GY | 1 |
Mehta, S | 1 |
Slinn, G | 1 |
Stanbury, M | 1 |
Steeds, RP | 1 |
Townend, JN | 1 |
DiFrancesco, JC | 1 |
Umeojiako, WI | 1 |
Kanyal, R | 1 |
Gui, H | 1 |
Guo, YF | 1 |
Liu, X | 1 |
Zhang, JM | 1 |
Yang, YL | 1 |
Huang, GZ | 1 |
Liu, JG | 1 |
Bradley, A | 1 |
Sheridan, P | 1 |
Ashes, C | 2 |
Judelman, S | 2 |
Wijeysundera, DN | 1 |
Tait, G | 2 |
Mazer, CD | 2 |
Hare, GM | 2 |
Beattie, WS | 2 |
Eisenach, JC | 1 |
Wicker, JF | 1 |
Bronheim, D | 1 |
Wijeysundera, D | 1 |
Lu, HT | 1 |
Nordin, R | 1 |
Othman, N | 1 |
Choy, CN | 1 |
Kam, JY | 1 |
Leo, BC | 1 |
Ramsamy, G | 1 |
Goh, TH | 1 |
van Lier, F | 1 |
Schouten, O | 1 |
Hoeks, SE | 1 |
van de Ven, L | 1 |
Stolker, RJ | 1 |
Bax, JJ | 1 |
Poldermans, D | 1 |
Leizorovicz, A | 1 |
Lechat, P | 1 |
Cucherat, M | 1 |
Bugnard, F | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Evaluating Different Rate Control Therapies in Permanent Atrial Fibrillation: A Prospective, Randomised, Open-label, Blinded Endpoint Feasibility Pilot Comparing Digoxin and Beta-blockers as Initial Rate Control Therapy[NCT02391337] | Phase 4 | 161 participants (Actual) | Interventional | 2016-12-20 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
24 hour ambulatory heart-rate. (NCT02391337)
Timeframe: Within 12 months
Intervention | bpm (Mean) |
---|---|
Beta-blocker | 73.7 |
Digoxin | 78.9 |
B-type natriuretic peptide (BNP) at 6 months. (NCT02391337)
Timeframe: 6 months
Intervention | ng/L (Median) |
---|---|
Beta-blocker | 1209 |
Digoxin | 1057.5 |
Number of Participants with hospital admissions for cardiovascular events. (NCT02391337)
Timeframe: 12 months
Intervention | Participants (Count of Participants) |
---|---|
Beta-blocker | 12 |
Digoxin | 2 |
Composite functional status measures- 6 minute walking distance at 12 months. (NCT02391337)
Timeframe: 12 months
Intervention | metres (Median) |
---|---|
Beta-blocker | 329 |
Digoxin | 366 |
"The above parameters will be measured using echocardiography and diastolic indices.~E/e' - the ratio between early mitral inflow velocity and mitral annular early diastolic velocity." (NCT02391337)
Timeframe: 12 months
Intervention | Ratio of E/e' (Mean) |
---|---|
Beta-blocker | 10.8 |
Digoxin | 10.8 |
Number of participants requiring drug discontinuation due to adverse reactions. (NCT02391337)
Timeframe: 12 months
Intervention | Participants (Count of Participants) |
---|---|
Beta-blocker | 9 |
Digoxin | 2 |
A composite of adverse clinical events (NCT02391337)
Timeframe: 12 months
Intervention | Participants (Count of Participants) |
---|---|
Beta-blocker | 19 |
Digoxin | 11 |
The above parameters will be measured using echocardiography and diastolic indices (NCT02391337)
Timeframe: 12 months
Intervention | percentage of ejection fraction (Mean) |
---|---|
Beta-blocker | 59.8 |
Digoxin | 59.7 |
Number of Participants with Unplanned Hospital Admissions. (NCT02391337)
Timeframe: During the 12 month follow-up period.
Intervention | Participants (Count of Participants) |
---|---|
Beta-blocker | 19 |
Digoxin | 11 |
"As assessed using the EQ-5D-5L summary index questionnaires at both 6 and 12 months.~The range for summary index is from -0.594=worst score to 1=best score" (NCT02391337)
Timeframe: 12 months
Intervention | units on a scale (Mean) |
---|---|
Beta-blocker | 0.62 |
Digoxin | 0.66 |
As assessed using the AFEQT overall score at 12 months. The range for AFEQT overall score is from 0= complete disability to 100=no disability. (NCT02391337)
Timeframe: 12 months
Intervention | score on a scale (Mean) |
---|---|
Beta-blocker | 68.1 |
Digoxin | 75.6 |
"Patient-reported outcomes as assessed by the SF-36 questionnaire physical component score.~The physical component score ranges from 0-100 where higher value indicates better outcome." (NCT02391337)
Timeframe: Primary outcome at 6 months timepoint.
Intervention | score on a scale (Mean) |
---|---|
Beta-blocker | 29.7 |
Digoxin | 31.9 |
As assessed using the SF-36 version 2 global and specific scores at 12 months. All domains presented are between 0 to 100 scale where the higher score indicates better outcomes. (NCT02391337)
Timeframe: 12 months
Intervention | score on a scale (Mean) | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Physical Component Summary | Mental Component Summary | Physical Function Domain Score | Role Limitation Due to Physical Domain score | Role Limitation Due to Emotional Problems Domain score | Social Functioning Domain Score | Mental Health Domain | Energy/Vitality Domain Score | Pain Score | General Health Perception Domain Score | |
Beta-blocker | 29.4 | 51.3 | 27.5 | 32 | 40.7 | 43.3 | 51.8 | 42 | 41.9 | 39.6 |
Digoxin | 32.5 | 53.6 | 31.5 | 37 | 45.2 | 45.6 | 51.3 | 47.1 | 40.5 | 42.8 |
Convenience, compliance and cross-over data (NCT02391337)
Timeframe: 12 months
Intervention | Participants (Count of Participants) | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Death71940422 | Death71940423 | Lost to follow-up71940422 | Lost to follow-up71940423 | Withdrawn consent71940422 | Withdrawn consent71940423 | |||||||
yes | No | |||||||||||
Beta-blocker | 7 | |||||||||||
Digoxin | 4 | |||||||||||
Beta-blocker | 73 | |||||||||||
Digoxin | 77 | |||||||||||
Beta-blocker | 0 | |||||||||||
Digoxin | 2 | |||||||||||
Beta-blocker | 80 | |||||||||||
Beta-blocker | 1 | |||||||||||
Beta-blocker | 79 | |||||||||||
Digoxin | 79 |
1 review available for bisoprolol and Stroke
Article | Year |
---|---|
Bisoprolol for the treatment of chronic heart failure: a meta-analysis on individual data of two placebo-controlled studies--CIBIS and CIBIS II. Cardiac Insufficiency Bisoprolol Study.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Female; Heart Failure; Hospitalization; Humans; Male; Middl | 2002 |
3 trials available for bisoprolol and Stroke
Article | Year |
---|---|
Preventative effects of bisoprolol transdermal patches on postoperative atrial fibrillation in high-risk patients undergoing non-cardiac surgery: A subanalysis of the MAMACARI study.
Topics: Aged; Atrial Fibrillation; Bisoprolol; Humans; Postoperative Complications; Risk Factors; Stroke; Tr | 2021 |
A review of rate control in atrial fibrillation, and the rationale and protocol for the RATE-AF trial.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprolo | 2017 |
Impact of prophylactic beta-blocker therapy to prevent stroke after noncardiac surgery.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Dose-Response Relationship, Drug; Female; Humans; Inc | 2010 |
9 other studies available for bisoprolol and Stroke
Article | Year |
---|---|
Artery of Percheron ischaemic stroke revealed by brain MRI DWI/ADC sequences.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Bisoprolol; Brain Ischemia; Cerebral Arteries; Diffusi | 2017 |
Left ventricular hypertrophy diagnosed after a stroke: a case report.
Topics: Aged, 80 and over; Antihypertensive Agents; Bisoprolol; Cardiomyopathy, Hypertrophic; Chest Pain; Co | 2018 |
Effects of combination therapy with levamlodipine and bisoprolol on stroke in rats.
Topics: Animals; Antihypertensive Agents; Baroreflex; Bisoprolol; Drug Therapy, Combination; Heart Rate; Mal | 2013 |
Atrial fibrillation.
Topics: Aged; Antihypertensive Agents; Anxiety; Atrial Fibrillation; Bisoprolol; Comorbidity; Diabetes Melli | 2013 |
Selective β1-antagonism with bisoprolol is associated with fewer postoperative strokes than atenolol or metoprolol: a single-center cohort study of 44,092 consecutive patients.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Atenolol; Bisoprolol; Cohort Studies; Female; Humans; | 2013 |
Patient safety: anesthesiology contributions and supplements to the American Society of Anesthesiologists' Annual Meeting.
Topics: Adrenergic beta-1 Receptor Antagonists; Atenolol; Bisoprolol; Female; Humans; Male; Metoprolol; Post | 2013 |
Does β selectivity really affect outcome?
Topics: Adrenergic beta-1 Receptor Antagonists; Atenolol; Bisoprolol; Female; Humans; Male; Metoprolol; Post | 2014 |
In reply.
Topics: Adrenergic beta-1 Receptor Antagonists; Atenolol; Bisoprolol; Female; Humans; Male; Metoprolol; Post | 2014 |
Biatrial thrombi resembling myxoma regressed after prolonged anticoagulation in a patient with mitral stenosis: a case report.
Topics: Antihypertensive Agents; Atrial Fibrillation; Bisoprolol; Diagnosis, Differential; Directive Counsel | 2016 |